Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Patients with cyanotic congenital heart disease (CCHD), with or without the presence of Eisenmenger physiology, are quite susceptible to the development of thrombosis.1 Cerebrovascular events as well as pulmonary thrombosis are two of the most common clinical manifestations in this group of patients with detrimental effects on quality of life and overall prognosis.2–4 Prevention of these episodes is challenging, as a number of different pathogenetical mechanisms of cerebral or pulmonary thrombosis have been previously proposed. Administration of antithrombotic therapy especially in patients with Eisenmenger physiology is controversial due to the increased risk of bleeding complications, which sometimes can be fatal in this population. Thus, the use of antithrombotic therapy in patients with Eisenmenger syndrome is under debate with still no existence of official recommendations.5 Early diagnosis of thrombosis based on the available imaging modalities may lead to a more effective therapeutic management of these patients.
Four possible mechanisms of thrombi formation in the pulmonary arteries of patients with Eisenmenger syndrome have been proposed.6 These include the existence of local vascular injury secondary to pulmonary hypertension, platelet dysfunction or factor deficiencies leading to hypercoagulopathy, cell aggregation due to decreased blood flow in the pulmonary arteries and embolic sources. On the other hand, systemic emboli secondary to atrial …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.